Resurrecting a reimbursement rule on 340B drugs that the U.S. Supreme Court struck down in 2021, CMS is once again proposing to update Medicare payment rates for drugs purchased under the 340B prescription drug discount program to better reflect what hospitals actually pay for the outpatient drugs.